Status:
UNKNOWN
Early Diagnosis of Oxaliplatin-induced Portal Hypertension
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Gastroesophageal Varices
Colorectal Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. However, hepatotoxic...
Eligibility Criteria
Inclusion
- Male or female patients aged 18-75
- Had a history of oxaliplatin-based chemotherapy for the treatment of colorectal cancer surgery;
Exclusion
- Combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease.
- With colorectal cancer required further anti-tumor treatment
Key Trial Info
Start Date :
August 31 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2022
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT04524650
Start Date
August 31 2020
End Date
September 30 2022
Last Update
August 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroenterology and Hepatology
Shanghai, Shanghai Municipality, China, 200032